研究

研究室

教授:櫛山 暁史(クシヤマ アキフミ)

役職名

教授

研究室

薬物治療学

最終学歴

東京大学大学院医学系研究科博士課程(2006年3月)

学位

博士(医学)(東京大学:2006年3月)

講義科目

薬物治療学Ⅲ,Ⅵ、症例解析演習Ⅰ,Ⅱ、臨床薬学基礎実習、事前実務実習、病院薬学コース、海外医療研修コース、薬剤師生涯学習講座、大学院薬物治療学特論・演習

専門分野

インスリン抵抗性、尿酸代謝、動脈硬化、糖尿病発症機序、インスリン治療患者の意識、糖尿病と骨、糖尿病と消化管障害、心電波形の周波数解析、レセプトデータを用いた処方動向と予後、糖尿病網膜症の新規治療の開発、新規腎保護薬物の開発、Drug Repositioning、

研究課題

核酸代謝と生活習慣病の関連、分泌蛋白と生活習慣病の関連、糖尿病合併症の予後規定因子、生活習慣病の薬物治療学、生活習慣病の非薬物治療学

所属学会

日本糖尿病学会、日本日本分子生物学会、日本血管生物医学会、日本痛風核酸代謝学会、日本内科学会

学会活動

日本成人病生活習慣病学会評議員、日本血管生物医学会評議員

学内委員

薬剤師国家試験問題検討委員会、国家試験・CBT対策委員会、バイオハザード安全委員会、大学院運営委員会

社会活動

日本医療機能評価機構医療事故情報等収集事業分析班委員、糖尿病専門医、内科認定医、RIZAP医療顧問、東久留米駅前クリニック顧問、博報堂メディカルアドバイザー

依頼講演(2018年以前)

1. 糖尿病患者に対するMCG解析 櫛山 暁史 第57回 日本人間ドック学会学術大会/長野県:7月29日,2016年
2. 高齢者糖尿病治療について 櫛山 暁史 超高齢社会のトータルケアを考える会/東京都:2016年9月14日
3. 安全かつ効果的に結果にコミットできる減量方法の確立を目指して 櫛山 暁史第38回日本肥満学会/大阪府: 2017年10月7日
4. Gout with Diabetes Akifumi KUSHIYAMA The 3rd Experts in Asia for Gout and hyperuricemia(EAGER)/台湾・高雄市:2018年9月9日

原著(2018年以前)

Nakatsu Y, Matsunaga Y, Yamamotoya T, Ueda K, Inoue MK, Mizuno Y, Nakanishi M, Sano T, Yamawaki Y, Kushiyama A, Sakoda H, Fujishiro M, Ryo A, Ono H, Minamino T, Takahashi SI, Ohno H, Yoneda M, Takahashi K, Ishihara H, Katagiri H, Nishimura F, Kanematsu T, Yamada T, Asano T. Prolyl Isomerase Pin1 Suppresses Thermogenic Programs in Adipocytes by Promoting Degradation of Transcriptional Co-activator PRDM16. Cell Rep. 2019 Mar 19;26(12):3221-3230.e3. doi:10.1016/j.celrep.2019.02.066. PubMed PMID: 30893596.

Inoue MK, Yamamotoya T, Nakatsu Y, Ueda K, Inoue Y, Matsunaga Y, Sakoda H, Fujishiro M, Ono H, Morii K, Sasaki K, Masaki T, Suzuki Y, Asano T, Kushiyama A. The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model. Int J Mol Sci. 2018 Dec 10;19(12). pii: E3967. doi:10.3390/ijms19123967. PubMed PMID: 30544662;

Yamazaki H, Kushiyama A, Sakoda H, Fujishiro M, Yamamotoya T, Nakatsu Y, Kikuchi T, Kaneko S, Tanaka H, Asano T. Protective Effect of Sex Hormone-Binding Globulin against Metabolic Syndrome: In Vitro Evidence Showing Anti-Inflammatory and Lipolytic Effects on Adipocytes and Macrophages. Mediators Inflamm. 2018 Jun 25;2018:3062319. doi: 10.1155/2018/3062319. eCollection 2018. PubMed PMID:30046278;

Fujishiro M, Kushiyama A, Yamazaki H, Kaneko S, Koketsu Y, Yamamotoya T, Kikuchi T, Sakoda H, Suzuki R, Kadowaki T. Gastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus. World J Gastroenterol. 2017 Sep 28;23(36):6694-6704. doi:10.3748/wjg.v23.i36.6694. PubMed PMID: 29085214;

Pang Z, Kushiyama A, Sun J, Kikuchi T, Yamazaki H, Iwamoto Y, Koriyama H, Yoshida S, Shimamura M, Higuchi M, Kawano T, Takami Y, Rakugi H, Morishita R, Nakagami H. Glial fibrillary acidic protein (GFAP) is a novel biomarker for the prediction of autoimmune diabetes. FASEB J. 2017 Sep;31(9):4053-4063. doi:10.1096/fj.201700110R. Epub 2017 May 25. PubMed PMID: 28546444.

Yamamotoya T, Nakatsu Y, Kushiyama A, Matsunaga Y, Ueda K, Inoue Y, Inoue MK, Sakoda H, Fujishiro M, Ono H, Kiyonari H, Ishihara H, Asano T. Trk-fused gene (TFG) regulates pancreatic β cell mass and insulin secretory activity. Sci Rep. 2017 Oct 12;7(1):13026. doi: 10.1038/s41598-017-13432-x. PubMed PMID: 29026155;

Kushiyama A, Kikuchi T, Tanaka K, Tahara T, Takao T, Onishi Y, Yoshida Y, Kawazu S, Iwamoto Y. Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1. World J Diabetes. 2016 Jun 10;7(11):230-8. doi: 10.4239/wjd.v7.i11.230. Epub 2016 Jun 11. PubMed PMID: 27326345;

Okubo H, Kushiyama A, Sakoda H, Nakatsu Y, Iizuka M, Taki N, Fujishiro M, Fukushima T, Kamata H, Nagamachi A, Inaba T, Nishimura F, Katagiri H, Asahara T, Yoshida Y, Chonan O, Encinas J, Asano T. Involvement of resistin-like molecule β
in the development of methionine-choline deficient diet-induced non-alcoholic steatohepatitis in mice. Sci Rep. 2016 Jan 28;6:20157. doi: 10.1038/srep20157. PubMed PMID: 26818807

総説(2018年以前)

Okubo H, Kushiyama A, Nakatsu Y, Yamamotoya T, Matsunaga Y, Fujishiro M, Sakoda H, Ohno H, Yoneda M, Asano T. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. Int J Mol Sci. 2018 Oct 8;19(10). pii: E3064. doi:10.3390/ijms19103064. Review. PubMed PMID: 30297626;

Kushiyama A, Nakatsu Y, Matsunaga Y, Yamamotoya T, Mori K, Ueda K, Inoue Y, Sakoda H, Fujishiro M, Ono H, Asano T. Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as
Atherosclerosis and Nonalcoholic Steatohepatitis. Mediators Inflamm. 2016;2016:8603164. doi: 10.1155/2016/8603164. Epub 2016 Dec 14. Review. PubMed PMID: 28070145;

原著(2019年)

Treatment of two mitochondrial disease patients with a combination of febuxostat and inosine that enhances cellular ATP: Kamatani Na, Kushiyama A, Toyo-Oka Lb and Toyo-Oka Tc (aTsukuba International Clinical Pharmacology Clinic, bDepartment of Human Genetics, Graduate School of Medicine, University of Tokyo, cTohto Bunkyo Hospital and Tohto Kioi Clinic ), J Hum Genet, 64, 351-353 (2019)

Association of gait speed and grip strength with risk of cardiovascular events in patients on haemodialysis: a prospective study: Kuki Aa, Tanaka Kb,c, Kushiyama A Tanaka Yd, Motonishi Se, Sugano Ya, Furuya Tf and Ozawa Tg (aKitahachiouji Clinic, bHigashikurume Ekimae Clinic, cThe Division of Diabetes and Metabolism, The Institute for Adult Diseases, Asahi Life Foundation, dKumegawa tousekinaika Clinic, eHigashiyamato Nangai Clinic, f Higashikurume Clinic, gKodaira Kitaguchi Clinic) BMC Nephrol, 20, 196 (2019)

Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice: Inoue MKa, Matsunaga Yb, Nakatsu Ya, Yamamotoya Ta, Ueda Ka, Kushiyama A, Sakoda Hc, Fujishiro Md, Ono He, Iwashita Mf, Sano Tf, Nishimura Ff, Morii Kg, Sasaki Kg, Masaki Tg and Asano Ta. (aDepartment of Medical Science, Graduate School of Medicine, Hiroshima University, bCenter for Translational Research in Infection & Inflammation, School of Medicine, Tulane University, cDivision of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, d Division of Diabetes and Metabolic Diseases, Nihon University School of Medicine, eDepartment of Clinical Cell Biology, Graduate School of Medicine, Chiba University, f Section of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, gDepartment of Nephrology, Hiroshima University Hospital) Diabetol Metab Syndr, 11, 57 (2019)

Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice: Mizuno Ya, Yamamotoya Ta, Nakatsu Ya, Ueda Ka, Matsunaga Y,a,b, Inoue MKa, Sakoda Hc, Fujishiro Md, Ono He, Kikuchi Tf, Takahashi M, Morii Kg, Sasaki Kg, Masaki Tg, Asano Ta and Kushiyama A. (aDepartment of Medical Science, Graduate School of Medicine, Hiroshima University,  bCenter for Translational Research in Infection o& Inflammation, School of Medicine, Tulane University, cDivision of Neurology, Respirology, Endocrinology, and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, dDivision of Diabetes and Metabolic Diseases, Nihon University School of Medicine, eDepartment of Clinical Cell Biology, Graduate School of Medicine, Chiba University, fDivision of Diabetes and Metabolism, The Institute for Adult Diseases, Asahi Life Foundation, gDepartment of Nephrology, Hiroshima University Hospital) Int J Mol Sci, 20, pii: E4680(2019)

Characteristics and Early Hypoglycemic Medications of Patients at Risk of Progression to Type 2 Diabetes in Japan: A Retrospective Cohort Study of Health Checkup and Claims Data: Kanai N, Shono A, Kushiyama A and Akazawa M. Biol Pharm Bull, 42, 2016-2023 (2019)

総説(2019年)

Inoue MK, Nakatsu Y, Yamamotoya T, Hasei S, Kanamoto M, Naitou M, Matsunaga Y, Sakoda H, Fujishiro M, Ono H, Kushiyama A, Asano T:Pin1 Plays Essential Roles in NASH Development by Modulating Multiple Target Proteins, Cells, 8, pii: E1545 (2019)

国際学会

招待講演

Novel therapeutics for diabetic retinopathy: Kushiyama A. Symposium on Interdisciplinary Approach for the Development of Novel Diagnosis and Treatment of Retinal Diseases, 2019/12, Seoul, Korea

一般講演・ポスター発表

Relationship between plaque destabilization and glucose / nucleic acid metabolism. Kushiyama A, Takahashi M and Nakagami Ha. (aDepartment of Health Development and Medicine, Osaka University Graduate School of Medicine), Inaugural Joint Scientific Meeting of AVBS/ANZMS/AAVBM, 2019/9, Sydney, AUS

国内学会招待講演(2019年)

LDLの血管障害リスク~血糖・尿酸など~:櫛山暁史、第27回血管生物医学会学術集会、2019/12、神戸

Pin1 and Trk-fused geneTFG):novel regulators for β-cell mass and function:山本屋 武a、中津祐介a、櫛山暁史、石原寿光b、浅野知一郎a  (a広島大学大学院医歯薬保健学研究科医化学研究室、b日本大学医学部内科学系糖尿病代謝内科学分野) 、第62回糖尿病学会年次学術集会、2019/5、仙台

著書(2019年)

特集 糖尿病診療の”Q 現場の疑問に答えます、pp. 842-844、Medicina 5 薬物療法(経口血糖降下薬)SGLT2阻害薬の使い方、能登洋企画、医学書院、東京 (2019)

果糖による体脂肪や中性脂肪値、尿酸値への影響について教えてください。また、適切な摂取量についても教えてください。プラクティス・セレクション6 pp. 20-22、糖尿病の療養指導Q&A vol.2 野田光彦編集 医歯薬出版株式会社、東京 (2019)